Patenting costs cast a shadow on European biotech
Article Abstract:
The European Patent Office and the US Patent and Trademark Office have experienced an upsurge of patent applications from Europe. European biotech firms increasingly used patenting as a strategic tool and are continuing to do so, but high patenting costs cast a shadow on European biotech.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Building a strategy for maximizing intellectual property value
Article Abstract:
The managing of intellectual property (IP) requires the implementation of an IP strategy and standards that control the development of the IP portfolio. Strategy and tactics for managing an IP portfolio should infiltrate the biotech company from the business strategy to the product teams.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
The patent gamble: strategic insights for playing the worldwide patent game
Article Abstract:
Biotech companies seek international patent protection for their inventions to ensure long-term viability Methods to rein in an unruly patent program and begin the process of proactively managing the development of an international patent portfolio are discussed.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Building on the brand. Training crisis hits profession
- Abstracts: Thawing a frosty response. Paving the way. The best trained; the highest standards
- Abstracts: Ireland launches regenerative medicine research center. China steps up US biotech intellectual property land grab
- Abstracts: UK bidding war amidst merger mania. GM giants pair up to do battle. Europe responds to UK's GM field trials
- Abstracts: Collaborative research presents special problems for patent seekers. Vox populi and public policy: why should we care?